Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crysvita in TIO or ENS
NCT02722798Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Apr 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of burosumab in tumor-induced osteomalacia (TIO), epidermal nevus syndrome (ENS), sponsored by Kyowa Kirin. Started Apr 2016; status: completed.
02
Drugs
burosumab
03
Conditions
tumor-induced osteomalacia (TIO)epidermal nevus syndrome (ENS)
Beyond the preview
Go deeper on NCT02722798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722798.